文献速递白内障与屈光手术

医疗保险通道支付计划下白内障手术缓释皮质类固醇的使用与费用

Use and Cost of Sustained-Release Corticosteroids for Cataract Surgery Under the Medicare Pass-Through Program.
PubMed 文献 · JAMA Ophthalmol · 2023-01-01

这项横断面研究分析了2019年3月至2021年12月期间接受白内障手术的医疗保险按服务收费受益人的理赔数据,发现缓释皮质类固醇的使用率低(地塞米松眼内混悬液9%为0.8%,地塞米松眼内插入剂为1.7%),且费用高于传统术后眼药水。作者认为,医疗保险通道支付计划的高定价可能阻碍了这些产品的使用。

要点

  • 在4,252,532例白内障手术中,0.8%使用了地塞米松眼内混悬液9%,1.7%使用了地塞米松眼内插入剂,两者使用率在研究期间均上升。
  • 地塞米松眼内混悬液9%和地塞米松眼内插入剂的平均医疗保险允许费用分别为531.47美元和538.49美元,高于传统术后眼药水。
  • 作者认为,当前医疗保险报销规则可能不适用于白内障手术后的缓释皮质类固醇。

核心结论

  • 尽管缓释皮质类固醇可能提高依从性和患者便利性,但本研究发现其白内障手术中使用率低,且相对于传统术后眼药水增加了医疗系统费用。
  • 作者认为,由于这些新产品必须定价足够高才能符合医疗保险通道支付计划,不合理的高费用可能阻碍了其使用,提示当前医疗保险报销规则可能不适用于白内障手术后的缓释皮质类固醇。

研究设计与样本

  • 这项横断面研究分析了2019年3月至2021年12月期间接受至少1次白内障手术、且有至少12个月连续医疗保险注册的按服务收费受益人理赔数据。
  • 排除标准包括:年龄小于65岁、人口统计学信息缺失、每只眼接受超过1次白内障手术、手术当天接受超过1种皮质类固醇。
  • 共纳入4,252,532例白内障手术,由12,284名眼科医生施行;受益人平均(SD)年龄74.8(5.8)岁,男性1,730,811例(40.7%),女性2,521,721例(59.3%)。
  • 数据分析时间为2022年6月15日至12月4日。

主要发现

  • 在全部手术中,34,627名受益人(0.8%)接受了地塞米松眼内混悬液9%,73,430名(1.7%)接受了地塞米松眼内插入剂;两种药物的使用在研究期间均增加。
  • 地塞米松眼内混悬液9%和地塞米松眼内插入剂的平均(SD)医疗保险允许费用分别为531.47(141.52)美元和538.49(63.79)美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sustained-release corticosteroids offer the potential of improved compliance and greater patient convenience for anti-inflammatory treatment after cataract surgery. However, they are substantially more expensive than postoperative corticosteroid eye drops, which have historically been standard care. OBJECTIVE: To examine the use and cost of sustained-release corticosteroids in patients with Medicare who underwent cataract surgery in the US during the temporary pass-through reimbursement program period. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study examined Medicare fee-for-service (FFS) claims from beneficiaries with at least 12 continuous months of Medicare enrollment who underwent at least 1 cataract surgery from March 2019 through December 2021. Patients younger than 65 years, those with missing demographic information, those who had more than 1 cataract surgery on each eye, and those who received more than 1 corticosteroid on the day of surgery were excluded. Cataract surgeries with concurrent use of dexamethasone intraocular suspension 9% or dexamethasone ophthalmic insert were identified. Information on surgeon demographic characteristics and costs of surgery and drugs were extracted. Data were analyzed from June 15 to December 4, 2022. EXPOSURE: Use of dexamethasone intraocular suspension 9% or dexamethasone ophthalmic insert during cataract surgery. MAIN OUTCOME MEASURES: Utilization rate and cost of dexamethasone intraocular suspension 9% and dexamethasone ophthalmic insert among Medicare FFS beneficiaries who underwent cataract surgery. RESULTS: A total of 4 252 532 cataract surgeries in Medicare FFS beneficiaries (mean [SD] age, 74.8 [5.8] years; 1 730 811 male [40.7%] and 2 521 721 female [59.3%]) were performed by 12 284 ophthalmologists (8876 male [72.3%], 2877 female [23.4%], and 531 sex unknown [4.3%]). In all, 34 627 beneficiaries (0.8%) received dexamethasone intraocular suspension 9% and 73 430 (1.7%) received a dexamethasone ophthalmic insert; the use of both drugs increased over the study period. The mean (SD) Medicare allowed charges for dexamethasone intraocular suspension 9% and dexamethasone ophthalmic insert were $531.47 ($141.52) and $538.49 ($63.79), respectively. CONCLUSIONS AND RELEVANCE: Despite offering the potential of improved compliance and greater patient convenience, findings of this study suggest that sustained-release corticosteroid use during cataract surgery was low and associated with cost increases to the health care system vs conventional postoperative eye drops. As these new products must be priced high enough to qualify for the Medicare pass-through program, unreasonable cost may have been a deterrent to their use, suggesting that the current Medicare reimbursement rules may not be appropriate for sustained-release postoperative corticosteroids in cataract surgery.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Dai X, Chang DF, Chen A, et al. Use and Cost of Sustained-Release Corticosteroids for Cataract Surgery Under the Medicare Pass-Through Program. JAMA Ophthalmol. 2023. PMID: 37535374. doi:10.1001/jamaophthalmol.2023.3389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。